Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,861 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05953350RecruitingPhase 1/Phase 2
Hydroxychloroquine plus CDK4/6 medicine for advanced solid tumors
This trial tests whether adding hydroxychloroquine (a medicine that affects a cell recycling process called autophagy) can boost the anti-cancer effect of high-dose CDK4/6 inhibitor treatment in advanced solid tumors. It may help tumors respond better after prior CDK4/6 treatments have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT06656624RecruitingPhase 2
Ribociclib plus hormone therapy for advanced breast cancer
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
Nanjing, JiangsuAges 18–99 - NCT06937957RecruitingPhase 1
BR111 for advanced cancers
This is an early-phase study testing a new drug called BR111 for people with advanced solid tumors or B-cell lymphoma who have run out of effective options. The trial helps find the right dose and checks if the drug is safe.
Shanghai, Pudong New AreaAges 18 years+ - NCT06616987RecruitingPhase 2
Preventing neutropenia from sacituzumab govitecan in TNBC
This trial tests whether a drug called sacituzumab govitecan can help prevent a low white blood cell count (neutropenia) in people with metastatic triple-negative breast cancer. It is for patients who have already received some chemotherapy but need a new treatment option.
SeoulAges 19 years+ - NCT07527026RecruitingPhase 2
Camrelizumab and chemotherapy with radiation for advanced rectal cancer
This trial tests a combination of an immunotherapy drug (camrelizumab) with chemotherapy and radiation to shrink advanced rectal cancer before surgery. The goal is to help more patients have successful surgery with complete tumor removal.
Beijing, Beijing MunicipalityAges 18–75 - NCT06023758RecruitingPhase 2
Study of two drugs with or without chemo for HER2-positive stomach cancer
This study tests two new immunotherapy drugs (KN026 and KN046) with or without chemotherapy (XELOX) for people with a specific type of advanced stomach cancer that makes too much HER2 protein. The goal is to see if this combination can shrink tumors or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06595108Recruiting
Targeted therapy and radiation for advanced liver cancer
This trial tests a combination of immunotherapy (atezolizumab), targeted therapy (bevacizumab), and targeted radiation for advanced liver cancer that cannot be surgically removed. The goal is to see if this approach helps control the cancer.
Yongin-siAges 19–80 - NCT05414032RecruitingPhase 2
Using leftover DNA signals to guide treatment after head and neck cancer
This Phase 2 trial tests a drug strategy for people with locally advanced head and neck cancer linked to HPV status. It looks at “molecular residual disease” by measuring tumor DNA in blood and uses early response and tumor test results to see who may benefit.
TorontoAges 18 years+ - NCT05144152Recruiting
Testing M3 and FIT to predict polyp return in colon exams
This study checks how well two lab tests (M3 and FIT) can predict whether advanced colon polyps (adenomas) will come back. If you’ve had adenomas found on a prior colonoscopy, these results may help plan future surveillance.
Shatin, New TerritoriesAges 18 years+ - NCT07101679RecruitingPhase 2
Study of radiation, chemo, and immunotherapy for advanced pancreatic cancer
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–75 - NCT06512428RecruitingPhase 2
Simmitinib plus irinotecan for advanced esophageal cancer
This trial tests a new combination of two drugs—simmitinib (a targeted therapy) and irinotecan (a chemotherapy)—for people with advanced esophageal cancer that has stopped responding to one prior treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Heilongjiang, HarbinAges 18–70 - NCT06905405Recruiting
Imaging for early heart failure with stiff heart muscle (HFpEF)
This study uses advanced imaging to find early signs of a type of heart failure where the heart pumps well but doesn't relax properly (HFpEF). It may help if you have shortness of breath and a slightly enlarged heart chamber but don't yet have a clear heart failure diagnosis.
Sheffield, South YorkshireAges 18 years+ - NCT07460752RecruitingPhase 2
Alternative injection site for goserelin in breast cancer patients
This trial is testing whether giving the drug goserelin in a different spot on the body works just as well for suppressing ovarian function in premenopausal women with hormone receptor positive breast cancer. You may be a fit if you've already been on goserelin shots in your abdomen for at least 6 months.
Rochester, MinnesotaAges 18–50 - NCT06770439RecruitingPhase 2
New drug plus chemotherapy for advanced pancreatic cancer
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hangzhou, ZhejiangAges 18 years+ - NCT06446050RecruitingEarly Phase 1
Modified stem cells for advanced colorectal cancer
This trial tests a new treatment using special stem cells (modified to boost your immune system) for people with advanced colorectal cancer. It is for patients who are 18 or younger and whose cancer has not responded to or cannot be treated with standard therapies.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06043973RecruitingPhase 3
Almonertinib plus anlotinib for first-line advanced lung cancer
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
Jinan, ShandongAges 18–75 - NCT07052669RecruitingPhase 3
Shorter Chemo-Radiation Plus Immunotherapy for Stage III Lung Cancer
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06214156RecruitingPhase 1/Phase 2
T3011 for advanced melanoma
This trial tests a new treatment, T3011, which is a virus that targets and kills cancer cells while also boosting your immune system. It's for people with advanced melanoma, and the goal is to see if it can shrink tumors and help you live longer.
BeijingAges 18 years+ - NCT06335914Recruiting
Dual PET scans for advanced prostate cancer
This study tests whether two kinds of PET scans, one targeting PSMA and one targeting sugar uptake (FDG), can help doctors better understand advanced prostate cancer. If you have prostate cancer that has spread (metastatic) and still responds to hormone therapy, the scans may help guide your treatment.
Toronto, OntarioAges 18 years+ - NCT06760364RecruitingPhase 1
CHT102 for Advanced Pancreatic Cancer with Mesothelin
This trial tests a new treatment called CHT102 for people with advanced pancreatic cancer that has a specific protein (mesothelin) on their tumor cells. It's for those who have already tried standard treatments without success or couldn't tolerate them.
TianjinAges 18–70 - NCT07238283RecruitingPhase 3
New liposome chemo combo for first-line pancreatic cancer
This trial tests a new form of chemotherapy (irinotecan liposome) combined with two other chemo drugs, compared to a standard treatment, for people with metastatic pancreatic cancer who haven't had chemo yet.
Beijing, Beijing MunicipalityAges 18–75 - NCT06433609RecruitingPhase 2
ADC plus immunotherapy for advanced HER2-negative breast cancer
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07285382RecruitingPhase 2
Dalpiciclib plus letrozole for advanced HR+ HER2- breast cancer
This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.
Dalian, LiaoningAges 18–75 - NCT06154538RecruitingPhase 2
Immunotherapy plus chemo vs. chemo alone for advanced colorectal cancer before surgery
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced colorectal cancer.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,861 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.